Clinical trials: Dermatitis, Exfoliative
Healthy Volunteers, Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
The study is divided in 3 parts, starting with the safety assessment of BPR277 ointment in Healthy volunteers (Part 1). If found to be well tolerated in Part 1, BPR277 ointment will be assessed in two different patients groups to…
- Conditions
- Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
- Trial name
- 3 (NCT01428297)
- Testing
- BPR277 ointment (controlled application), BPR277 ointment, BPR277
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Epidermolytic Ichthyosis, Palmoplantar Keratoderma
Epidermal Growth Factor Receptor Inhibition for Keratinopathies
Epidermal growth factor receptor (EGFR) signaling plays a key role in regulating epidermal cell proliferation, survival, and differentiation.
- Conditions
- Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita
- Trial name
- NCT06545695
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Netherton Syndrome
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus.
- Trial name
- NS-DUPI (NCT04244006)
- Testing
- Dupilumab Prefilled Syringe
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Toulouse
Netherton Syndrome
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years or older.
- Trial name
- NCT05856526
- Testing
- Spesolimab - solution for infusion, Spesolimab - solution for injection
- Where
- 28 sites in United States, Australia and 12 more
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim
Ichthyosis, Netherton Syndrome
Defining the Skin and Blood Biomarkers of Ichthyosis
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment.
- Trial name
- NCT03417856
- Where
- 4 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Netherton Syndrome
Gene Therapy for Netherton Syndrome
Netherton Syndrome is a serious skin disorder caused by damage in a gene called SPINK5. This gene controls the formation of a protein called LEKTI, which important for skin barrier function.
- Trial name
- NCT01545323
- Testing
- One 20cm2/10cm2 autologous skin sheet graft
- Where
- 2 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Netherton Syndrome
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease.
- Trial name
- NCT05211830
- Testing
- SXR1096 cream
- Where
- 5 sites in Austria, France and 2 more
- Volunteers
- 9 people
- Sponsor
- Sixera Pharma
Pityriasis Rubra Pilaris
Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit.
- Trial name
- NCT03975153
- Testing
- guselkumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oregon Health and Science University
Pityriasis Rubra Pilaris
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS…
- Trial name
- NCT06444399
- Testing
- Deucravacitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Pityriasis Rubra Pilaris
Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
15 patients with PRP will be treated with ixekizumab for 24 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit and week-24 visit.
- Trial name
- NCT03485976
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Oregon Health and Science University
Netherton Syndrome
Clinical Trial Using Humira in Netherton Syndrome
The main objective of this studies therapeutic : to determine the effect of Adalimumab (HumiraR) on clinical inflammatory manifestations of patients with Netherton syndrome after 3 months of treatment , with a post treatment…
- Trial name
- AntiTNF-SN (NCT02113904)
- Testing
- Adalimumab
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pityriasis Rubra Pilaris
Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP)
The purpose of this study is to valuate the clinical efficacy of Bimzelx therapy in adults with Pityriasis Rubra Pilaris.
- Trial name
- NCT07497620
- Testing
- Bimekizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Netherton Syndrome, Healthy
Natural History and Biological Study of Netherton Syndrome
This study aims at studying the natural history of Netherton syndrome (NS), to identify the consequences of LEKTI deficiency on the immune system and to characterize new molecular mechanisms involved in the disease.
- Trial name
- NSnatbio (NCT02081313)
- Testing
- Biopsy, Blood sample
- Where
- France
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Netherton Syndrome
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
Netherton syndrome is a genetic condition that can result in abnormal skin functioning. People with this condition often have red and scaling skin; sparse or short hair; and problems with absorption of medicines or chemicals that…
- Trial name
- NCT00208026
- Testing
- Pimecrolimus 1% Cream
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Children's Hospital of Philadelphia
Psoriasis Vulgaris, Psoriatic Arthritis
A Phase 4 Clinical Study of Brodalumab
This study [4827-005 (post market)] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003…
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma
- Trial name
- NCT04183881
- Testing
- Brodalumab 210mg SC
- Where
- Japan
- Volunteers
- 138 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis, Psoriasis Palmaris
Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines
French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults have been developed by the psoriasis research group of the French Society of Dermatology using literature available until July 2017…
- Conditions
- Psoriasis, Psoriasis Palmaris, Psoriasis Inverse, Psoriasis Vulgaris
- Trial name
- NCT05144165
- Testing
- Experts consensus
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre of Evidence of the French Society of Dermatology
Syndromic Ichthyoses, CHILD Syndrome
Novel Treatment for Syndromic Ichthyoses
This is an open label-pilot study to assess the efficacy and safety of a novel cholesterol-lovastatin topical solution in children with rare syndromic ichthyoses.
- Conditions
- Syndromic Ichthyoses, CHILD Syndrome, Smith Lemli Opitz Syndrome, Conradi Syndrome
- Trial name
- NCT01110642
- Testing
- Lovastatin
- Sponsor
- Northwestern University
Smith Lemli Opitz Syndrome, CHILD Syndrome
Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism
Background: Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder. It can cause birth defects and developmental delays. There is no cure for SLOS or other inherited diseases related to cholesterol production or storage.
- Conditions
- Smith Lemli Opitz Syndrome, CHILD Syndrome, Lathosterolosis, Desmosterolosis
- Trial name
- NCT05047354
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Ichthyosis, Autosomal Recessive Congenital Ichthyosis
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
The ichthyoses are a group of lifelong genetic disorders which share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation.
- Conditions
- Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma
- Trial name
- NCT03041038
- Testing
- Secukinumab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Netherton Syndrome
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
Netherton syndrome (NS) is a rare autosomal recessive disease and no systemic treatment or standard of care currently exists for patients with NS.
- Trial name
- NCT05388903
- Testing
- DS-2325a
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo